Trial Profile

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Nofazinlimab (Primary)
Indications Adenocarcinoma; Gastric cancer; Leiomyosarcoma; Liver cancer; Lymphoma; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors CStone Pharmaceuticals

Most Recent Events

28 Nov 2022 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
19 May 2022 Planned End Date changed from 31 Mar 2022 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com